KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

TherapeuticsMD (TXMD) EBT (2016 - 2025)

TherapeuticsMD's EBT history spans 16 years, with the latest figure at -$580000.0 for Q4 2025.

  • For Q4 2025, EBT fell 798.8% year-over-year to -$580000.0; the TTM value through Dec 2025 reached -$653000.0, up 72.13%, while the annual FY2025 figure was -$653000.0, 72.13% up from the prior year.
  • EBT reached -$580000.0 in Q4 2025 per TXMD's latest filing, down from $50000.0 in the prior quarter.
  • In the past five years, EBT ranged from a high of $50.2 million in Q4 2021 to a low of -$47.4 million in Q3 2021.
  • Average EBT over 5 years is -$4.4 million, with a median of -$1.2 million recorded in 2023.
  • Peak YoY movement for EBT: soared 219.16% in 2021, then tumbled 798.8% in 2025.
  • A 5-year view of EBT shows it stood at $50.2 million in 2021, then decreased by 3.38% to $48.5 million in 2022, then tumbled by 103.27% to -$1.6 million in 2023, then skyrocketed by 105.24% to $83000.0 in 2024, then crashed by 798.8% to -$580000.0 in 2025.
  • Per Business Quant, the three most recent readings for TXMD's EBT are -$580000.0 (Q4 2025), $50000.0 (Q3 2025), and $545000.0 (Q2 2025).